Abstract

In seeking a continued Cooperative Agreement, the Allegheny Community Clinical Oncology Program (A-CCOP), will extend its performance of clinical research protocols by the addition of organizational components in contiguous catchment areas of Western Pennsylvania and Eastern Ohio. The consortium will then include the Division of Medical Oncology/AGH, Division of Radiation Oncology/AGH, Hematology/Oncology Associates, Inc., Jameson Memorial Hospital, Sewickley Valley Hospital, Frick Community Health Center, Western Reserve Care System and Washington Hospital. Performance will also be enhanced by the addition of two speciality research bases, M.D. Anderson Hospital and Brain Tumor Cooperative Group, thus allowing greater opportunity for professional participants and their oncologic patient population to subscribe to nationally approved clinical trials. Existing relationships will continue with multidisciplinary Southwest Oncology Group and the following specialty groups: National Surgical Adjuvant Breast and Bowel Project and Radiation Therapy Oncology Group. Successful data management and quality assurance techniques will be extended to the new A- CCOP component organization. In keeping with broadened initiatives of the Division of Cancer Prevention and Control of the National Cancer Institute, cancer control protocols emanating from research bases also will be implemented. The A-CCOP headquarters and Data Management Center will evaluate and coordinate resources and capabilities of participant components and personnel to maximize control protocol performance. Protocols will address early detection, prevention, screening, pretreatment evaluation, treatment, continuing care and rehabilitation. Appropriate cancer treatment and control research protocols will be introduced throughout the A-CCOP. Methods of involving other professionals in the component organizations will be explored. Their collaboration in treatment, control, and educational programs should promote valuable exchange of scientific knowledge, imparting quality cancer control and increased awareness in the community. Disadvantaged populations within the catchment areas will be identified to assure proportional access to A-CCOP programs.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035117-10
Application #
3557521
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1983-09-15
Project End
1995-05-31
Budget Start
1993-06-01
Budget End
1994-05-31
Support Year
10
Fiscal Year
1993
Total Cost
Indirect Cost

  Institution

Name
Allegheny-Singer Research Institute
Department
Type
DUNS #
033098401
City
Pittsburgh
State
PA
Country
United States
Zip Code
15212

  Publications

Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Tangen, Catherine M; Hussain, Maha H A; Higano, Celestia S et al. (2012) Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 188:1164-9
Scosyrev, Emil; Ely, Benjamin W; Messing, Edward M et al. (2011) Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int 108:693-9
Harigopal, Malini; Barlow, William E; Tedeschi, Greg et al. (2010) Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol 176:1639-47
Albain, Kathy S; Barlow, William E; Shak, Steven et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65
Albain, Kathy S; Barlow, William E; Ravdin, Peter M et al. (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:2055-63
Sonpavde, Guru; Goldman, Bryan H; Speights, V O et al. (2009) Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115:4104-9
Tubbs, Raymond; Barlow, William E; Budd, G Thomas et al. (2009) Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 27:3881-6
Dhodapkar, Madhav V; Hoering, Antje; Gertz, Morie A et al. (2009) Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood 113:793-6

Showing the most recent 10 out of 25 publications